Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.

Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

Jun 13 2019, 4:35 PM EDT

Stock Overview

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Exchange</th>
<th>Market Cap</th>
<th>Last Price</th>
<th>S2-Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>TECH</td>
<td>Nasdaq</td>
<td>7.89b</td>
<td>$208.34</td>
<td>$132.75 - $216.470001</td>
</tr>
</tbody>
</table>

Investor Relations

David Clair
T: 646-277-1266
ir@bio-techne.com

Management Team

Charles (Chuck) Kummeth
President and Chief Executive Officer

Jim Hippel
Chief Financial Officer

David Eansor
President, Protein Sciences Segment

Kim Kelderman
President, Diagnostics and Genomics

Brenda Furlow
General Counsel, Secretary and Chief Compliance Officer

Bio-Techne Corporation
614 McKinley Place NE
Minneapolis, MN 55413

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.